Compare Cardinal Health Inc (CAH) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Procter & Gamble Co — how do they compare? Cardinal Health Inc trades at $228.8 (market cap $53.89B), while Procter & Gamble Co trades at $146.15 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 6.3× Cardinal Health Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| CAH | PG | |
|---|---|---|
Market Cap | $53.89B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $239.71 | $167.18 |
52-Week Low | $146.04 | $138.10 |
Enterprise Value | $58.87B | $365.64B |
Dividend Yield | 0.89% | 2.92% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Procter & Gamble (PG) trades at $148.37, up 0.9% with a neutral technical outlook. The company maintains strong fundamentals with $84.28B revenue and 19.16% net income margin, consistently beating earnings estimates. Recent dividend declaration of $1.09 and WNBA partnership highlight stable returns and brand expansion. Analyst consensus is bullish with 53.85% buy ratings and $161.71 price target, though premium valuation metrics suggest cautious optimism.
PG offers steady growth with reliable dividends but faces margin pressure from rising costs. The stock's premium valuation requires sustained earnings growth to justify upside. Near-term resistance at $150 presents a key level to watch, while support at $145 provides downside protection. Institutional activity remains mixed amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
